Denmark · Delayed Price · Currency is DKK ALK-Abelló Earnings Call Transcripts
Fiscal Year 2026
-
Q1 saw revenue and EBIT exceed guidance, driven by strong tablet and anaphylaxis sales, especially in Europe and North America. Upgraded full-year outlook reflects continued momentum, with significant investments in growth and R&D, and key advances in peanut allergy and neffy.
-
Strong revenue and profit growth in 2025 enabled a resumed dividend and continued investment in R&D, production, and sustainability. All board proposals, including an updated remuneration policy and board re-elections, were approved. Shareholders discussed production, AI, and market expansion.
Fiscal Year 2025
-
Strong 2025 results with 15% revenue growth, 26% EBIT margin, and robust expansion in tablets and anaphylaxis products. 2026 guidance targets 11–15% revenue growth, continued double-digit tablet and anaphylaxis sales, and ongoing investment in R&D and infrastructure.
-
Q3 delivered double-digit revenue and EBIT growth, driven by strong pediatric tablet launches, new partnerships, and robust performance across all regions and product lines. The full-year outlook was raised, with continued investment in growth initiatives and a strong balance sheet.
-
Q2 delivered strong revenue and EBIT growth, driven by pediatric tablet launches and adrenaline auto-injectors, prompting an upgraded full-year outlook. Europe and North America led segment growth, with new product rollouts and strategic partnerships supporting momentum.
-
The company targets over 10% annual growth and a 25% EBIT margin by 2025, driven by expanding its allergy tablet portfolio, especially with new pediatric indications and strong European sales. Strategic partnerships, new product launches like Nefy, and a robust pipeline in food allergy and anaphylaxis support long-term growth.
-
Q1 revenue rose 12% to DKK 1.5 billion, led by 22% tablet sales growth and strong pediatric uptake. EBIT margin improved to 31%, and guidance for 2025 remains confident with 9–13% revenue growth expected. Neffy and pediatric launches are set to drive further expansion.
-
Strong financial growth in 2024 was driven by tablet sales and strategic execution, with a focus on reinvestment over dividends. The board and auditor were re-elected, and the Allergy Plus strategy aims for continued expansion and sustainability.
Fiscal Year 2024
-
Revenue grew 15% year-over-year, driven by strong European tablet sales and strategic execution, with EBIT up 65% and margin expansion. 2025 guidance projects 9%-13% revenue growth and a 25% EBIT margin, with Neffy and pediatric launches as key drivers.
-
Q3 delivered 18% organic revenue growth and a 10-point EBIT margin increase, driven by strong tablet sales and cost efficiencies. The outlook remains robust, with new product launches and the Neffy in-licensing deal expected to fuel future growth.
-
Secured exclusive rights to Neffy, a needle-free adrenaline nasal spray, targeting major growth in the anaphylaxis market, with launches in Europe and Canada from 2025. The deal is expected to be earnings-accretive within a few years and supports long-term strategic and financial goals.
-
Q2 saw 21% organic revenue growth, led by strong tablet sales in Europe, driving upgrades to full-year revenue and EBIT margin guidance. The Allergy+ strategy is progressing, with regulatory advances for pediatric tablets and ongoing cost optimization supporting long-term growth.
-
The updated strategy targets doubling treated patients by 2030, expanding into food allergy and anaphylaxis, and maintaining AIT leadership. Financial goals include 10%+ annual sales growth and a 25% EBIT margin, supported by disciplined capital allocation, pipeline expansion, and operational efficiency.